scholarly journals Prognostic value of the C‐reactive protein to albumin ratio in esophageal cancer: A systematic review and meta‐analysis

2019 ◽  
Vol 36 (1) ◽  
pp. 54-61 ◽  
Author(s):  
Yan Wang ◽  
Xu Hu ◽  
Yu Huang ◽  
Wen‐Ying Xu ◽  
Yan‐Ming Wu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Esophageal Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein

scholarly journals Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Zhenhua Liu ◽  
Hongtai Shi ◽  
Longyun Chen
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
Cochrane Library ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Pre Treatment

Abstract Background In recent years, the role of pre-treatment C-reactive protein/albumin ratio (CAR) in prognosis of esophageal cancer (EC) has been investigated by several studies. This meta-analysis aimed to provide a more accurate and objective assessment of the prognostic value of pre-treatment CAR in EC. Methods Studies assessing the role of pre-treatment CAR in prognosis of EC were searched from PubMed, Embase and the Cochrane Library (last update by April 16, 2019). The hazard ratios (HRs) of CAR and the corresponding 95% CIs for overall survival (OS) or cancer-specific survival (CSS) in EC were extracted for pooled analysis. Results A total of eight observational studies including 2255 patients were collected. The pooled analysis showed that high CAR was related to worse OS in EC (pooled HR = 1.81; 95% CI = 1.40–2.35; P < 0.001). Subgroup analyses showed that the negative correlation between the CAR and OS was consistently demonstrated in subgroups stratified by country, pathological type, and cut-off value (P < 0.05). However, there was no relation between CAR and OS in subgroup of patients receiving neoadjuvant chemotherapy at a proportion of 100% (HR = 1.15, 95% CI = 0.56–2.69; P = 0.715). In addition, high CAR was also related to worse CSS in EC (pooled HR = 2.61; 95% CI = 1.67–4.06; P < 0.001). Conclusions High pre-treatment CAR was an adverse prognostic factor for EC patients. More large-sample clinical trials are still needed to verify the prognostic value of pre-treatment CAR in EC.

scholarly journals Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis

2014 ◽  
Vol 15 (19) ◽  
pp. 8075-8081 ◽  
Author(s):  
Tian-Liang Zheng ◽  
Ke Cao ◽  
Cui Liang ◽  
Kai Zhang ◽  
Hai-Zhou Guo ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals C-Reactive Protein to Albumin Ratio in Colorectal Cancer: A Meta-Analysis of Prognostic Value

Dose-Response ◽  
2019 ◽  
Vol 17 (4) ◽  
pp. 155932581988981 ◽  
Author(s):  
Qiang-ping Zhou ◽  
Xiu-jiang Li
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Tumor Diameter ◽  
C Reactive Protein ◽  
Free Survival ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Serum Carcinoembryonic Antigen

Background: The relationship between pretreatment C-reactive protein to albumin ratio (CAR) and colorectal cancer (CRC) prognosis has been extensively studied in various tumors. However, little is known on CAR and its association with prognosis in CRC. This study aims to investigate the prognostic value of pretreatment CAR in CRC. Methods: We conducted a systematic search of MEDLINE, EMBASE, and Cochrane Library databases for eligible studies evaluating the associations of CAR with survival and/or clinicopathology of CRC. Overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS), and clinicopathological features were synthesized and compared. Results: Nine studies including 3431 patients were analyzed in this meta-analysis. Pooled results showed that elevated pretreatment CAR was associated with poor OS (pooled hazards ratio [HR]: 2.18, 95% confidence interval [CI]: 1.70-2.78, P < .001) and DFS/RFS (pooled HR: 2.36, 95% CI: 1.40-3.98, P < .001). Moreover, elevated pretreatment CARs were correlated with male patients, large tumor diameter, late III-IV tumor node metastasis stage tumors, high serum carcinoembryonic antigen and carbohydrate antigen 19-9, and presence of lymphatic invasion and venous invasion. Conclusion: Elevated pretreatment CAR could be an adverse prognostic indicator in patients with CRC.

Sign in / Sign up

Export Citation Format

Share Document